Last reviewed · How we verify
GK567
GK567 is a glucokinase activator that enhances glucose metabolism in pancreatic beta cells to stimulate insulin secretion.
GK567 is a glucokinase activator that enhances glucose metabolism in pancreatic beta cells to stimulate insulin secretion. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | GK567 |
|---|---|
| Also known as | GK567: Metronidazole Gel 0.75% |
| Sponsor | Galderma R&D |
| Drug class | Glucokinase activator |
| Target | Glucokinase (GCK) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | Phase 3 |
Mechanism of action
Glucokinase activators work by increasing the catalytic activity of glucokinase, an enzyme that acts as a glucose sensor in pancreatic beta cells. By enhancing glucokinase activity, GK567 lowers the glucose threshold needed to trigger insulin secretion, thereby improving glycemic control in a glucose-dependent manner. This mechanism is intended to reduce hypoglycemia risk compared to other insulin secretagogues.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disorders
Key clinical trials
- An Open, Uncontrolled Study of GK567 in the Deodorization of Malodorous Fungating Neoplastic Tumours (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GK567 CI brief — competitive landscape report
- GK567 updates RSS · CI watch RSS
- Galderma R&D portfolio CI